title: Pharmacological strategies for reduction of lipid availability.
authors.affiliation: Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceutical Corporation, East Hanover, New Jersey 07936, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Foley
authors.forename: R C
authors.initials: RC
authors.lastname: Anderson
authors.forename: P A
authors.initials: PA
authors.lastname: Bell
authors.forename: B F
authors.initials: BF
authors.lastname: Burkey
authors.forename: R O
authors.initials: RO
authors.lastname: Deems
authors.forename: C
authors.initials: C
authors.lastname: de Souza
authors.forename: B E
authors.initials: BE
authors.lastname: Dunning
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D051381:Rats
chemical_list: D005227:Fatty Acids; D007328:Insulin; C090949:N(6)-cyclohexyl-2-O-methyladenosine; D000241:Adenosine